抗肿瘤分子靶向药物相关性腹泻研究进展  

Research progress on diarrhea induced by molecular-targeted agents

作　　者：王施元 王致红 李春雨 李国辉 WANG Shi-yuan;WANG Zhi-hong;LI Chun-yu;LI Guo-hui(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院、北京协和医学院肿瘤医院,北京100021

出　　处：《药学学报》2021年第12期3377-3384,共8页Acta Pharmaceutica Sinica

基　　金：北京市科技计划项目(Z181100001618003)。

摘　　要：近年来,抗肿瘤药物的研发焦点从细胞毒性药物逐渐转向分子靶向药物,这类药物通过干扰癌细胞中过度表达或突变的分子,从而抑制肿瘤生长。与传统的化疗方案相比,分子靶向治疗是一种高特异性且不良反应较轻的新型治疗方法,但是分子靶向药物引起的不良反应也不容忽视。腹泻是临床上较为常见的不良反应之一,不仅降低患者的生活质量,还会成为临床安全用药的制约因素。本文对近十年来分子靶向药物相关性腹泻的文献进行归纳和分析,以期为相关研究和临床合理安全用药提供参考。In recent years,the focus of anti-cancer agents has gradually shifted from cytotoxic chemotherapy to molecular-targeted agents that interfere with frequently overexpressed or mutated molecules in cancer cells.Compared with cytotoxic chemotherapy,molecular-targeted therapy is a new biological therapy with higher specificity and lower toxicity,however,the adverse reactions caused by molecular-targeted agents cannot be ignored.Diarrhea is one of the most common adverse drug reactions,which could seriously affect the quality of life and even lead to treatment discontinuation and consequently decreased cancer control.To provide a reference for relevant research and clinical medication,we review the current reports on the incidence,pathogenic mechanism,and management of diarrhea induced by the molecular-targeted agents.

关 键 词：腹泻 抗肿瘤药物 分子靶向药物 酪氨酸激酶抑制剂 不良反应 合理用药 

分 类 号：R969[医药卫生—药理学]